| Page 5 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

Author(s): 
Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML
Primary Author: 
Gisriel SD
Journal Title: 
Archives of Pathology & Laboratory Medicine
Original Publication Date: 
Mar 2025

Context.—: Standardized bone marrow reporting specifically for

Bone Marrow Disease(s): 

Advancing drug development in myelodysplastic syndromes

Author(s): 
Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji R, Sekeres MA, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K
Primary Author: 
Mina A
Journal Title: 
Blood Advances
Original Publication Date: 
Mar 2025

Bone Marrow Disease(s): 

EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial

Author(s): 
Jang JH, Tomuleasa C, Oliynyk H, Lanamtieng T, Park J, Kim Y, Jung J, Russo P, Lim SM, Peffaultde Latour R
Primary Author: 
Jang JH
Journal Title: 
EJHaem
Original Publication Date: 
Mar 2025

Introduction: SB12 demonstrated equivalence to reference eculizumab (ECU) in complement inhibitor-naïve patients with

Bone Marrow Disease(s): 

The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Author(s): 
Hill A, Hotermans C, Pirozzi G
Primary Author: 
Hill A
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Mar 2025
Bone Marrow Disease(s): 

The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome

Author(s): 
Jang JH, Han B, Jung J, Russo P, Kulasekararaj AG
Primary Author: 
Jang JH
Journal Title: 
BioDrugs
Original Publication Date: 
Mar 2025

Eculizumab, a humanized

Bone Marrow Disease(s): 

Heterogeneity in Health-Related Quality of Life of Patients with Aplastic Anemia: A Latent Profile Analysis

Author(s): 
Wu G, Li X, Ren X, Huang J, Zhang X, Liang T, Sun L, Hao M, Kuang Z, Li X, Zhang Q, Xu L, Zheng Y, Xie W
Primary Author: 
Wu G
Journal Title: 
Patient Preference and Adherence
Original Publication Date: 
Mar 2025

Purpose: Concerns over health-related quality of life (HRQOL) in patients with

Bone Marrow Disease(s): 

2025 San Francisco - Bay Area Patient and Family Conference

WHO SHOULD ATTEND?

Register for the 2025 San Francisco Bay Area Patient and Family Conference
Event Date: 
Sat, 07/19/2025 - 10:30am (EDT)
Conference Event Type: 

AAMDSIF Supports the Accelerating Kids' Access to Care Act

AAMDSIF Supports the Accelerating Kids' Access to Care Act.

On March 26, 2025, AAMDSIF joined with 212 additional patient advocacy and medical center organizations in urging members of the US Congress to pass the Accelerating Kids’ Access to Care Act.
Passage of this bill will permit faster, more thorough care, for children with complex medical conditions.

Please view the PDF below.

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the

ABSTRACT